Contineum Therapeutics (CTNM) Common Equity (2023 - 2026)
Contineum Therapeutics (CTNM) posted quarterly Common Equity of $239.7 million for Q2 2026, up 39.83% year-over-year from $171.4 million in Q2 2025, and down 4.15% quarter-over-quarter from $250.0 million in Q1 2026.
Contineum Therapeutics (CTNM) Common Equity (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $239.7 million for Q2 2026.
- In Q2 2026, Common Equity rose 39.83% year-over-year to $239.7 million; the TTM figure through Jun 2026 stood at $239.7 million (up 39.83% YoY), while the FY2025 annual figure was $261.0 million, up 31.77% from the prior year.
- Common Equity for Q2 2026 stood at $239.7 million, down from $250.0 million in the prior quarter.
- The five-year high for Common Equity was $261.0 million in Q4 2025, with the low at -$97.5 million in Q1 2023.
- The 4-year median for Common Equity is $182.6 million (2025), against an average of $111.1 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 492.38% in 2024, then declined 21.2% in 2025.
- Contineum Therapeutics' Common Equity stood at -$67.9 million in 2023, then jumped by 391.55% to $198.1 million in 2024, then soared by 31.77% to $261.0 million in 2025, then declined by 8.17% to $239.7 million in 2026.
- Business Quant data shows CTNM's Common Equity at $239.7 million in Q2 2026, $250.0 million in Q1 2026, and $261.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Contineum Therapeutics | 533.73 Mn | 533.73 Mn | - | 239.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.66 Mn |
| Mar 31, 2026 | 250.04 Mn |
| Dec 31, 2025 | 260.99 Mn |
| Sep 30, 2025 | 180.47 Mn |
| Jun 30, 2025 | 171.39 Mn |
| Mar 31, 2025 | 184.77 Mn |
| Dec 31, 2024 | 198.07 Mn |
| Sep 30, 2024 | 210.23 Mn |
| Jun 30, 2024 | 217.50 Mn |
| Mar 31, 2024 | -75.63 Mn |
| Dec 31, 2023 | -67.94 Mn |
| Sep 30, 2023 | -61.15 Mn |
| Jun 30, 2023 | -55.43 Mn |
| Mar 31, 2023 | -97.46 Mn |